In human prostate cancer, genomic alterations of ETS-related genes, principally ERG, often occur as fusions between an androgen receptor-regulated gene promoter of TMPRSS2 and ETS transcription factors and are detected in about 50% of tumors [56, 57]. The gene discussed is TMPRSS2; the disease is prostate carcinoma.